Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Merck Serono
- 16 Aug 2018 New trial record